Rerouting the GPS Directing Immunotherapy in Endometrial Cancer

Rhea Jangra; Neesha C Dhani

doi:10.1158/1078-0432.CCR-23-1953

Rerouting the GPS Directing Immunotherapy in Endometrial Cancer

Clin Cancer Res. 2023 Nov 14;29(22):4521-4523. doi: 10.1158/1078-0432.CCR-23-1953.

Authors

Rhea Jangra¹, Neesha C Dhani¹

Affiliation

¹ Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada.

PMID: 37698948
DOI: 10.1158/1078-0432.CCR-23-1953

Abstract

Mismatch repair (MMR) status alone is insufficient to guide the use of PD-(L)1 monotherapy in patients with endometrial cancer. Additional biomarkers, including tumor mutational burden and combined positive score, may help to identify patients with MMR-proficient tumors with a high probability of benefit from PD-(L)1 monotherapy, and those with MMR-deficient tumors who might require combination strategies. See related article by Oaknin et al., p. 4564.

Publication types

Comment

MeSH terms

Biomarkers, Tumor
Colorectal Neoplasms* / pathology
DNA Mismatch Repair
Endometrial Neoplasms* / drug therapy
Endometrial Neoplasms* / genetics
Female
Humans
Immunotherapy
Neoplastic Syndromes, Hereditary* / pathology

Substances

Biomarkers, Tumor